FDA Drug Approvals Targeting GPCR Mechanisms, 2021 to 2026
G-protein-coupled receptors sit behind a large share of approved small molecules and peptides, so regulatory and clinical teams working on a GPCR-directed candidate are rarely without precedent. Knowing which GPCR products the FDA has actually approved, in which review divisions, and under what indication language shapes decisions about comparator choice, endpoint selection, labeling expectations, and where a first-in-class claim is defensible.
The analysis below reviews Drugs@FDA records for products approved between 2021 and mid-2026 that act primarily through a GPCR. Each entry is identified by active ingredient, receptor target and receptor class, therapeutic area, and original approval date, with the resulting distribution across therapeutic areas and receptor families set out alongside.
Want to ask Rhizome your own regulatory questions? Try it for free.
FDA drug approvals targeting GPCR mechanisms, 2021 to 2026
G-protein-coupled receptors (GPCRs) remain the single most productive target family in small-molecule and peptide drug development, and the FDA's approval record since 2021 reflects that. Across Drugs@FDA, at least eighteen distinct products approved between 2021 and mid-2026 act primarily through a GPCR, spanning class B secretin-family receptors (the incretin and glucagon receptors), class A aminergic and peptide receptors, lipid-sensing receptors, and chemokine receptors. The therapeutic footprint is unusually broad: cardiometabolic disease, migraine, schizophrenia, insomnia, multiple sclerosis and ulcerative colitis, gynecology and menopause, ANCA-associated vasculitis, chronic-kidney-disease pruritus, hepatorenal syndrome, stem-cell mobilization in multiple myeloma, and opioid-overdose reversal.
The clearest theme is the dominance of incretin biology. Beyond that, the period produced several genuine first-in-class GPCR agents, including the first muscarinic-agonist antipsychotic (Cobenfy), the first oral C5a-receptor antagonist (Tavneos), and the first neurokinin-3 receptor antagonist for menopausal vasomotor symptoms (Veozah).
Snapshot of GPCR-targeted approvals since 2021
| Product | Active ingredient | GPCR target (receptor class) | Therapeutic area | Original FDA approval |
|---|---|---|---|---|
| Wegovy | semaglutide | GLP-1 receptor agonist (class B) | Obesity / cardiometabolic | Jun 2021 375 |
| Mounjaro | tirzepatide | GIP + GLP-1 receptor agonist (class B) | Type 2 diabetes | May 2022 354 |
| Zepbound | tirzepatide | GIP + GLP-1 receptor agonist (class B) | Obesity / OSA | Nov 2023 357 |
| Foundayo | orforglipron | GLP-1 receptor agonist, oral (class B) | Cardiometabolic | Apr 2026 479 |
| Zegalogue | dasiglucagon | Glucagon receptor agonist (class B) | Severe hypoglycemia | Mar 2021 435 |
| Qulipta | atogepant | CGRP receptor antagonist (class B) | Migraine prevention | Sep 2021 225 |
| Zavzpret | zavegepant | CGRP receptor antagonist (class B) | Acute migraine | Mar 2023 231 |
| Cobenfy | xanomeline / trospium | M1/M4 muscarinic agonist (class A) | Schizophrenia | Sep 2024 36 |
| Quviviq | daridorexant | Orexin OX1R/OX2R antagonist (class A) | Insomnia | Jan 2022 332 |
| Ponvory | ponesimod | S1P receptor-1 modulator (class A) | Relapsing MS | Mar 2021 271 |
| Velsipity | etrasimod | S1P receptor 1/4/5 modulator (class A) | Ulcerative colitis | Oct 2023 259 |
| Myfembree | relugolix (combination) | GnRH receptor antagonist (class A) | Fibroids / endometriosis | May 2021 199 |
| Veozah | fezolinetant | Neurokinin-3 (NK3) receptor antagonist (class A) | Menopausal vasomotor symptoms | May 2023 66 |
| Korsuva | difelikefalin | Kappa opioid receptor agonist (class A) | CKD-associated pruritus | Aug 2021 90 |
| Tavneos | avacopan | Complement C5a receptor antagonist (class A) | ANCA-associated vasculitis | Oct 2021 185 |
| Terlivaz | terlipressin | Vasopressin V1a receptor agonist (class A) | Hepatorenal syndrome | Sep 2022 75 |
| Aphexda | motixafortide | CXCR4 chemokine receptor antagonist (class A) | Stem-cell mobilization (myeloma) | Sep 2023 41 |
| Opvee | nalmefene | Opioid receptor antagonist (class A) | Opioid-overdose reversal | May 2023 113 |
Cardiometabolic and endocrine: the incretin era
The largest cluster of GPCR approvals targets the incretin and glucagon receptors, all class B (secretin-family) GPCRs. Semaglutide (Wegovy) is a GLP-1 analogue that "acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor" 523; it entered the window as an obesity therapy in June 2021 375. Tirzepatide is a dual "GIP receptor and GLP-1 receptor agonist" 460, first approved as Mounjaro for glycemic control in type 2 diabetes in May 2022 459354 and then as Zepbound for chronic weight management in adults with obesity or overweight in November 2023 378357.
The period closed with two notable additions. Orforglipron (Foundayo), approved April 2026 479, is an orally administered agent whose labeling identifies "glucagon-like peptide-1 (GLP-1) receptor agonist activity" 480, extending the incretin class beyond injectable peptides into a small-molecule oral format. Dasiglucagon (Zegalogue), approved March 2021 435, works on the other side of glucose homeostasis: it is "a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors" 520, indicated for severe hypoglycemia in patients with diabetes weighing at least 20 kg 520.
Neurology and headache: CGRP-receptor gepants
Migraine has become a showcase for CGRP-receptor pharmacology, another class B GPCR. Atogepant (Qulipta) is a "calcitonin gene-related peptide (CGRP) receptor antagonist" 234 indicated for preventive treatment of migraine in adults 246, approved September 2021 225. Zavegepant (Zavzpret), the same mechanism 243, was approved March 2023 231 as an intranasal spray for acute treatment of migraine with or without aura 248. These small-molecule "gepants" sit alongside erenumab (Aimovig), the monoclonal antibody directed at the CGRP receptor itself rather than the ligand, which received a supplemental efficacy approval in this window 254. The oral gepants rimegepant (Nurtec ODT) and ubrogepant (Ubrelvy) also received labeling and indication supplements during the period.
Psychiatry and CNS: the first muscarinic-agonist antipsychotic
Cobenfy (xanomeline/trospium), approved September 2024 36, is the first antipsychotic to work through muscarinic rather than dopaminergic receptors. Its labeling attributes efficacy to xanomeline's "agonist activity at M1 and M4 muscarinic acetylcholine receptors in the central nervous system," with the co-formulated trospium acting as a peripheral muscarinic antagonist to limit cholinergic side effects 39. It is indicated for schizophrenia in adults 39. Both components engage class A muscarinic GPCRs, but as agonist and antagonist respectively.
Sleep medicine: dual orexin-receptor antagonism
Daridorexant (Quviviq), approved January 2022 332, acts "through antagonism of orexin receptors," blocking orexin A and orexin B at the OX1R and OX2R receptors to suppress wake drive 336. It is indicated for adults with insomnia characterized by difficulties with sleep onset and/or maintenance 340. Orexin receptors are class A peptide GPCRs, and the dual-antagonist approach continues a mechanism established by earlier agents in the class.
Immunology and neurology: sphingosine-1-phosphate receptor modulators
Two S1P receptor modulators, both acting on class A lipid-sensing GPCRs, were approved in the window. Ponesimod (Ponvory), approved March 2021 271, is "a sphingosine 1-phosphate (S1P) receptor 1 modulator" that blocks lymphocyte egress from lymph nodes 286, indicated for relapsing forms of multiple sclerosis 540. Etrasimod (Velsipity), approved October 2023 259, is a broader "S1P receptor modulator that binds with high affinity to S1P receptors 1, 4, and 5" 289, indicated for moderately to severely active ulcerative colitis in adults 289. The two illustrate how receptor-subtype selectivity within one GPCR family is being tuned for different autoimmune indications.
Women's health and menopause
Relugolix, formulated with estradiol and norethindrone acetate as Myfembree, is a gonadotropin-releasing hormone (GnRH) receptor antagonist 536, approved May 2021 199 for heavy menstrual bleeding associated with uterine fibroids and later for moderate-to-severe pain from endometriosis 214. The GnRH receptor is a class A peptide GPCR. Distinct from hormonal suppression, fezolinetant (Veozah), approved May 2023 66, is "a neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B binding on the KNDy neuron" to modulate the thermoregulatory center 530, indicated for moderate-to-severe vasomotor symptoms due to menopause 532. Veozah was the first NK3-receptor antagonist approved for this indication.
Rheumatology, nephrology, and dermatology
Avacopan (Tavneos), approved October 2021 185, is "a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a," blocking C5a-mediated neutrophil activation 188. It is an adjunctive treatment for severe active ANCA-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) 188, and was the first oral C5a-receptor antagonist. Difelikefalin (Korsuva), approved August 2021 90, is "a kappa opioid receptor (KOR) agonist" 96 indicated for moderate-to-severe pruritus associated with chronic kidney disease in adults on hemodialysis 96. As a peripherally restricted kappa-opioid agonist, it exploits a class A GPCR for an antipruritic rather than analgesic effect.
Hepatology and critical care
Terlipressin (Terlivaz), approved September 2022 75, is "a synthetic vasopressin analogue with twice the selectivity for vasopressin V1 receptors versus V2 receptors" 533, acting on class A vasopressin GPCRs to raise renal blood flow by reducing portal hypertension. It is indicated to improve kidney function in adults with hepatorenal syndrome and rapid reduction in kidney function 534.
Hematology and oncology support
Motixafortide (Aphexda), approved September 2023 41, is "an inhibitor of the C-X-C Motif Chemokine Receptor 4 (CXCR4)" that blocks binding of the ligand CXCL12/SDF-1 518, disrupting stem-cell anchoring in the marrow. It is indicated in combination with filgrastim to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma 518. CXCR4 is a class A chemokine GPCR, a target more familiar from HIV and oncology biology than from conventional small-molecule pharmacology.
Addiction and emergency medicine
Nalmefene (Opvee), approved May 2023 113, "is an antagonist at opioid receptors" with a longer duration of action than naloxone 522, indicated for emergency treatment of known or suspected opioid overdose in patients aged 12 and older 522. A nalmefene autoinjector (Zurnai) followed in August 2024 136. Opioid receptors are class A GPCRs, and several buprenorphine reformulations acting as partial mu-opioid agonists (for example Brixadi, approved May 2023 100) also reached the market, alongside the meloxicam/rizatriptan combination Symbravo (January 2025 35), whose triptan component engages 5-HT1B/1D serotonin GPCRs.
What the pattern shows
Three observations stand out for regulatory and competitive-intelligence purposes. First, class B secretin-family receptors (GLP-1, GIP, glucagon, CGRP) drove both the highest-volume approvals and the most commercially significant ones, and the arrival of an oral GLP-1 receptor agonist signals a shift away from injectable peptides. Second, several approvals were deliberate first-in-class moves against long-validated but previously undrugged GPCRs, notably muscarinic agonism for schizophrenia, C5a-receptor antagonism for vasculitis, and NK3-receptor antagonism for menopause. Third, receptor-subtype selectivity, rather than a new target entirely, increasingly differentiates products within a class, as seen across the S1P modulators and the CGRP-receptor gepants. A reader tracking a specific indication or receptor subfamily would find it worth asking Rhizome directly for the underlying review documents, pivotal-trial endpoints, and any post-marketing or exclusivity details tied to each of these approvals.